Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.14218/JCTH.2013.00008 http://scihub22266oqcxt.onion/10.14218/JCTH.2013.00008 C4521271!4521271!26355274     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Clin+Transl+Hepatol 2013 ; 1 (1): 75-8 Nephropedia Template TP {{tp|p=26355274|t=2013. Development of Tivantinib as Treatment for Hepatocellular Carcinoma |pdf=|usr=}}{{26355274}} gab.com Text Development of Tivantinib as Treatment for Hepatocellular Carcinoma JO: J Clin Transl Hepatol http://www.kidney.de/pget.php?&tw=1&pmid=26355274 #FOAvip Hepatocellular carcinoma (HCC) is a rapidly rising cause of liver-related death worldwide. Most patients are diagnosed at an advanced stage of disease, when systemic therapy is the only viable option for treatment. Significant strides have been made in the molecular understanding of HCC development and growth stimulation. The c-Met pathway has been found to be an important pathway in half of all patients with HCC. HCC tumors with high c-Met activation are associated with an aggressive phenotype and poor prognosis. Tivantinib is a MET receptor tyrosine kinase inhibitor with a broad spectrum of anti-tumor effects currently being studied for the treatment of HCC. Phase I and II data are available for tivantinib in the treatment of solid tumors, including HCC. There appears to be an adequate safety profile, with the main side-effect being neutropenia. In HCC patients with elevated c-Met activity, tivantinib results in an improved time to progression of 2.7 months, compared with 1.4 months in placebo-treated patients. Further studies are ongoing, but early data suggest that tivantinib is a therapy that deserves close attention in the coming years for patients with HCC. Twit Text FOAVip Development of Tivantinib as Treatment for Hepatocellular Carcinoma ????J Clin Transl Hepatol http://www.kidney.de/pget.php?&tw=1&pmid=26355274 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26355274 #FOAvip English Wikipedia <ref>{{Cite pmid|26355274}}</ref> Development of Tivantinib as Treatment for Hepatocellular Carcinoma #MMPMID26355274 Au J; Frenette C J Clin Transl Hepatol 2013[Sep]; 1 (1): 75-8 PMID26355274show ga Hepatocellular carcinoma (HCC) is a rapidly rising cause of liver-related death worldwide. Most patients are diagnosed at an advanced stage of disease, when systemic therapy is the only viable option for treatment. Significant strides have been made in the molecular understanding of HCC development and growth stimulation. The c-Met pathway has been found to be an important pathway in half of all patients with HCC. HCC tumors with high c-Met activation are associated with an aggressive phenotype and poor prognosis. Tivantinib is a MET receptor tyrosine kinase inhibitor with a broad spectrum of anti-tumor effects currently being studied for the treatment of HCC. Phase I and II data are available for tivantinib in the treatment of solid tumors, including HCC. There appears to be an adequate safety profile, with the main side-effect being neutropenia. In HCC patients with elevated c-Met activity, tivantinib results in an improved time to progression of 2.7 months, compared with 1.4 months in placebo-treated patients. Further studies are ongoing, but early data suggest that tivantinib is a therapy that deserves close attention in the coming years for patients with HCC. äDevelopment of Tivantinib as Treatment for Hepatocellular Carcinoma (epmc).pdf DeepDyve Pubget Overpricing